Protective efficacy of the 5-aminolevulinic acid for cisplatin nephrotoxicity

• Project/Area Number: 15K08604
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Kawasaki Medical School
• Principal Investigator: Yamatsuji Tomoki 川崎医科大学, 医学部, 准教授 (40379730)
• Co-Investigator(Kenkyū-buntansha): 猶本 良夫 川崎医科大学, 医学部, 教授 (00237190) ; 高岡 宗徳 川崎医科大学, 医学部, 講師 (50548568)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
• Keywords: アミノレブリン酸 / 5-アミノレブリン酸（ALA） / 5-アミノレブリン酸

Outline of Final Research Achievements

Cisplatin used for treatment of the gastric cancer induce renal injury and large quantities transfusion to prevent the renal failure. 5-aminolevulinic acid (ALA) is the matter which is important as a precursor of the heme compound such as hemoglobin and cytochrome, the catalase, shows the important physiological function of most. In a renal failure model with the cisplatin administration using the rat, 5-ALA inhibited renal injury. We planned a clinical phase I study for establishing the new renal failure prophylaxis that could surpass fluid therapy from an aspect of the quality of life in large quantities using ALA. Patients with unresectable gastric cancer are enrolled. Primary endpoint: Safety of 5-ALA as the prevention of renal failure supplement. During Cisplatin/S-1 treatment, 5-ALA phosphoric acid is taken before the cisplatin administration. Eight patients were enrolled as of December 2017. The adverse events Grade 3 or more were not found.

Research Products

• [Journal Article] Feasibility of oral administration of S-1 as adjuvant chemotherapy in gastric cancer: 4-week S-1 administration followed by 2-week rest vs. 2-week administration followed by 1-week rest. (2015)
  • Author(s): Yamatsuji T,Fujiwara Y, Matsumoto H,Hato S,Namikawa T, Hanazaki K,Takaoka M,Hayashi J,Shigemitsu K,Yoshida K,Urakami A,Uno F,Nishizaki M,Kagawa S,Ninomiya M,Fujiwara T,Hirai T,Nakamura M,Haisa M,Naomoto Y
  • Journal Title: Molecular and Clinical Oncology Volume: 3(3) Pages: 527-532
  • Peer Reviewed
• [Presentation] 5-アミノレブリン酸によるシスプラチン腎毒性抑制作用の臨床応用 (2017)
  • Author(s): 山辻知樹，近藤健介，石田尚正，磯田竜太郎，湯川拓郎 高岡宗徳，林 次郎，吉田和弘，深澤拓也，中島一毅，浦上 淳 森田一郎，羽井佐 実，杭ノ瀬昌彦，猶本良夫
  • Organizer: 第118回日本外科学会定期学術集会
• [Presentation] 食道癌術後再建胃管癌の診断および治療法の検討( Cases of Carcinoma in the Reconstructed Gastric Tube Following Esophagectomy for Esophageal Cancer). (2016)
  • Author(s): 山辻知樹,吉田将和,石田尚正,櫻井早也佳,湯川拓郎,平林葉子,高岡宗徳,深澤拓也,林次郎,吉田和弘,繁光薫,中島一毅,浦上淳,森田一郎,杭ノ瀬昌彦,末廣満彦,物部泰昌,春間賢,河本博文,猶本良夫
  • Organizer: 第92回日本消化器内視鏡学会総会
  • Place of Presentation: 神戸コンベンションセンター,神戸
• [Presentation] 5-アミノレブリン酸によるシスプラチン腎毒性抑制作用の臨床応用 (2015)
  • Author(s): 猶本良夫
  • Organizer: 第6回川崎医科大学学術集会
  • Place of Presentation: 川崎医科大学（岡山県倉敷市）
  • Year and Date: 2015-08-01